Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Sana Biotechnology

Tracked across 11 events · 415 articles · First seen Mar 26, 2025 · Last active Sep 08, 2026

Sentiment
35
Attention
8
Events
11
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Sana Biotechnology entered a strategic collaboration with Mayo Clinic to advance the development of SC451, its investigational cell therapy for type 1 diabetes. This collaboration is expected to accelerate the clinical development and potential market adoption of SC451, positively impacting Sana Biotechnology's stock price and future prospects.
Apr 13, 2026 · 6 articles
4 20
Business
Impact: Sana Biotechnology sold 21,607,878 shares of its common stock through an ATM facility, raising approximately $69 million, which extends its cash runway to mid-2027. This capital raise is positive for the company's financial stability and ongoing operations.
May 15, 2026 · 6 articles
4 75
Regulatory
Impact: Sana Biotechnology achieved EU MDR certification for its Aphranel® MagiCCrystal CaHA Filler, allowing it to expand its market presence in the European Union and solidify its position as a global regenerative aesthetics brand originating from China.
May 28, 2026 · 6 articles
4 50
Tech
Impact: Sana Biotechnology is the journal that published the findings of the fPE7max research, providing a platform for the scientific community to learn about this breakthrough.
Jul 02, 2026 · 6 articles
7 80
Tech
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's immunotherapy Pembrolizumab, met its primary and secondary endpoints in a Phase 3 trial involving 1,137 patients…
Impact: The index rose 4.4% to a record high following the announcement, reflecting increased investor interest in biotech stocks. The event is a positive catalyst for the sector.
Aug 19, 2026 · 126 articles
2 0
Business
Impact: Dhavalkumar Patel>>> is currently Executive Vice President and Chief Scientific Officer of Sana Biotechnology>>>.
Jun 12, 2026 · 6 articles
6 0
Regulatory
Impact: The Sana Biotechnology is mentioned as a benchmark to highlight the disproportionately high market valuation of Regencell Bioscience Holdings compared to other companies in the sector.
Apr 25, 2026 · 206 articles
4 60
Business
Impact: The Sana Biotechnology has risen 13% this year, reflecting the strong biotech sector performance that supports IPOs like Scribe's.
Jul 06, 2026 · 25 articles
8 0
Business
Impact: Sana Biotechnology jointly developed UBT251 with Novo Nordisk, a triple agonist drug that showed significant weight loss in trials.
Feb 24, 2026 · 13 articles
4 30
Business
Impact: Collaborator of IASO Bio; unaffected directly.
Jul 20, 2026 · 6 articles
4 0
Tech
May 26, 2026 · 9 articles
60 Sana Biotechnology climbed to record highModerna Merck mRNA...
ERGEN INTELLIGENCE
Track Sana Biotechnology live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.